Proteomic identification of salivary biomarkers of type-2 diabetes.

The identification of biomarkers to noninvasively detect prediabetes/diabetes will facilitate interventions designed to prevent or delay progression to frank diabetes and its attendant complications. The purpose of this study was to characterize the human salivary proteome in type-2 diabetes to identify potential biomarkers of diabetes. Whole saliva from control and type-2 diabetic individuals was characterized by multidimensional liquid chromatography/tandem mass spectrometry (2D-LC-MS/MS). Label-free quantification was used to identify differentially abundant protein biomarkers. Selected potential biomarkers were then independently validated in saliva from control, diabetic, and prediabetic subjects by Western immunoblotting and ELISA. Characterization of the salivary proteome identified a total of 487 unique proteins. Approximately 33% of these have not been previously reported in human saliva. Of these, 65 demonstrated a greater than 2-fold difference in abundance between control and type-2 diabetes samples. A majority of the differentially abundant proteins belong to pathways regulating metabolism and immune response. Independent validation of a subset of potential biomarkers utilizing immunodetection confirmed their differential expression in type-2 diabetes, and analysis of prediabetic samples demonstrated a trend of relative increase in their abundance with progression from the prediabetic to the diabetic state. This comprehensive proteomic analysis of the human salivary proteome in type-2 diabetes provides the first global view of potential mechanisms perturbed in diabetic saliva and their utility in detection and monitoring of diabetes. Further characterization of these markers in a larger cohort of subjects may provide the basis for new, noninvasive tests for diabetes screening, detection, and monitoring.

[1]  A. Stavljenic-Rukavina,et al.  Proinflammatory factors in saliva as possible markers for periodontal disease. , 2005, Collegium antropologicum.

[2]  B. Lamarche,et al.  Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes Published, JLR Papers in Press, March 3, 2007. , 2007, Journal of Lipid Research.

[3]  A. Piwowar,et al.  Concentration of Leukocyte Elastase in Plasma and Polymorphonuclear Neutrophil Extracts in Type 2 Diabetes , 2000, Clinical chemistry and laboratory medicine.

[4]  J. Nicolau,et al.  Study of the buffering capacity, pH and salivary flow rate in type 2 well-controlled and poorly controlled diabetic patients. , 2007, Oral health & preventive dentistry.

[5]  John R Yates,et al.  The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. , 2008, Journal of proteome research.

[6]  Mary E D'Alton,et al.  Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. , 2007, Journal of proteome research.

[7]  Michael K. Coleman,et al.  Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. , 2006, Journal of proteome research.

[8]  M. Atkinson,et al.  α1-Antitrypsin Protects β-Cells From Apoptosis , 2007, Diabetes.

[9]  Michael K. Coleman,et al.  Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. , 2005, Analytical chemistry.

[10]  José Manuel Fernández-Real,et al.  Innate immunity, insulin resistance and type 2 diabetes , 2008, Trends in Endocrinology & Metabolism.

[11]  R. Beavis,et al.  A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. , 2003, Analytical chemistry.

[12]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[13]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[14]  S. Sadayappan,et al.  Cardiac isoform of alpha-2 macroglobulin--a new biomarker for myocardial infarcted diabetic patients. , 2006, Atherosclerosis.

[15]  V. Headings,et al.  Decreased total carbonic anhydrase esterase activity and decreased levels of carbonic anhydrase 1 isozyme in erythrocytes of type II diabetic patients , 2007, Biochemical Genetics.

[16]  L. Hansson,et al.  Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. , 2008, International journal of cardiology.

[17]  S. Dasari,et al.  Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. , 2007, Journal of proteome research.

[18]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[19]  J. X. Pang,et al.  Biomarker discovery in urine by proteomics. , 2002, Journal of proteome research.

[20]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[21]  C. Östenson,et al.  Serum protein patterns in newly diagnosed type 2 diabetes mellitus—influence of diabetic environment and family history of diabetes , 2008, Diabetes/metabolism research and reviews.

[22]  Shen Hu,et al.  Human saliva proteome analysis and disease biomarker discovery , 2007, Expert review of proteomics.

[23]  Robert A Hegele,et al.  Phenomics, lamin A/C, and metabolic disease. , 2007, The Journal of clinical endocrinology and metabolism.

[24]  J. Pachecka,et al.  Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence , 2006, Acta Diabetologica.

[25]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[26]  G. E. Oxford,et al.  Salivary EGF levels reduced in diabetic patients. , 2000, Journal of diabetes and its complications.

[27]  K. Chia,et al.  Markers of diabetic nephropathy. , 1998, Journal of diabetes and its complications.

[28]  Leonardo Pereira,et al.  Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. , 2007, Journal of proteome research.

[29]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[30]  J. Girona,et al.  Retinol‐binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes , 2007, Journal of internal medicine.

[31]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[32]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.